



Prof. Antonino Neri

Date of birth: December 20, 1957

Place of birth: Reggio Calabria, Italy

Address: via Tintoretto, 19, 20090 Buccinasco (MI), Italy

Telephone: 0250320420/3454627859

E-mail: antonino.neri@unimi.it

Nationality: Italian

EDUCATION AND TRAINING

- **1981** Degree in Medicine, University of Milan, with 110 votes out of 110 cum laude, with a thesis entitled " Membrane markers of normal and pathological lymphocyte subpopulations; study of the receptor for a B lymphoblastoid cell line (RPMI 1788). "
- **1984** Postgraduate degree in Hematology, University of Milan, vote 70 to 70 cum laude, with a thesis entitled "Study of receptors of differentiation in human acute leukemia."
- **1990** PhD in Experimental Hematology, University of Milan, with a thesis entitled: "The Role of the RAS oncogenes Family in the pathogenesis of lymphoid malignancies: molecular study of 234 cases."
- **2001** Postgraduate degree in Medical Genetics, University of Milan, vote 70 of 70 cum laude, with a thesis entitled: "Analysis of mutations of the gene fibroblast growth factor receptor 3 (FGFR3) involved in the translocation t (4; 14) (p16.3; q32) in multiple myeloma."
- **2003** Conferral of National Scientific Enabling to Full Professor (First Range) contest field 06 / D3 Blood Diseases, Oncology and Rheumatology.

WORK EXPERIENCE

- **01/11/2007-present** Confirmed Associate Professor of Blood and Hematopoietic Organs Diseases, University of Milan, under the agreement with Fondazione IRCCS Ca 'Granda-Ospedale Maggiore Policlinico, Milan.
- **01/01/2014-present** In charge of the UOS Research and Laboratory Foundation IRCCS Ca 'Granda-Ospedale Maggiore Policlinico, Milan.
- **1997-2005** Assistant Professor of Hematology at the School of Specialization in Hematology 1, School of Medicine, University of Milan.
- **24/01/2005-31/10/2007** Medical Director, discipline: "Laboratory of Experimental Hematology and Molecular Genetics", Fondazione IRCCS Ca 'Granda-Ospedale Maggiore Policlinico, Milan, with managerial position " Technical and professional high autonomy ".
- **01/01/1995-23/01/2005** Medical Director of first level range B- professional profile "Medicine Doctors," functional position "Medical Assistant" discipline: "Laboratory of Experimental Hematology

and Molecular Genetics" (Ospedale Maggiore IRCCS, Milan). Responsible for research group and oncohematology diagnostics.

- **02/09/1991-31/12/1994** Role Medical assistant at the Laboratory of Experimental Hematology and Molecular Genetics, IRCCS Ospedale Maggiore in Milan. Responsible for research group and oncohematology diagnostics.
- **01/02/1989-31/08/1991** Grantee (research nomination ex. Art. 36 del D.P.R. N° 617/1980) at Hematological Diagnostics Service, Ospedale Maggiore, I.R.C.C.S., Milan.
- **01/02/1985-31/01/ 1989** Post-doctoral research fellow at the laboratory of Dr. Riccardo Dalla Favera, Department of Pathology, New York University, Medical Center, New York, USA.
- **1982-1984** Organizer of the Laboratory of Flow Cytometry, Clinica Medica I^a, University of Milan, Italy.
- **01/11/1981 1981- 31/01/1985** Resident Doctor at Istituto di Clinica Medica I^a, University of Milan.

ASSISTENTIAL ACTIVITY

From the appointment of Medical Assistant (1991) in the discipline Laboratory of Experimental Hematology and Molecular Genetics, Ospedale Maggiore IRCCS, Milan, he performs the following care activities: activities of molecular diagnostics in the field of hematology at the Department of Hematology and Oncology; coordination of personnel involved in the molecular diagnosis of oncohematologic diseases; setting, implementation, monitoring and validation of new methods useful for identification and follow-up of cancer diseases, with a focus on hematological malignancies.

RESEARCH ACTIVITY

He began his research activity during university studies and continues to this day, as demonstrated by the important scientific production, including about 240 original papers in international scientific journals, and major scientific and academic awards.

AWARDS

- **1990** «Cecilia Cioffrese» Award, Fondazione Carlo Erba, for his activity in cancer research.
- **2005** International Award “San Valentino d’oro”, city of Terni, for his activity in cancer research.

DIDACTICAL ACTIVITY

- Teacher at the degree course of the School of Medicine and Surgery, University of Milan.
- Teacher at the degree course of Medical Biotechnology, University of Milan.
- Teacher at the degree course for Lab Technicians, University of Milan.
- Teacher at the Specialization School of Hematology I, University of Milan.
- Teacher at the Doctoral School of Experimental Hematology, University of Milan.
- Teacher at the Specialization School of Medical Genetics, University of Milan.
- Teacher at the Specialization School of Clinical Biochemistry.

ADVISORY ACTIVITIES

- Elected Member of the Executive Committee of the Italian Society of Experimental Hematology (SIES) (2010-2014).
- Vice President of the Italian Society of Experimental Hematology (SIES) (years 2012-2014).
- Member of the Italian Society of Hematology (SIE)
- Member of the Italian Society of Experimental Hematology (SIES).
- Member of the European Society of Hematology (EHA).
- Member of the American Society of Hematology (ASH).

EDITORIAL ACTIVITIES

Reviewer for articles in international scientific journals related to lymphoproliferative syndromes and monoclonal gammopathies: Clinical Cancer Research; Cancer Research; British Journal of Haematology; Genes Chromosomes and Cancer; Hematological Oncology; Haematologica; Blood.

MAJOR FIELDS OF RESEARCH

- immunophenotypic (monoclonal antibodies and flow cytometry) and functional characterization of leukemic cell populations
- molecular characterization of hematological neoplasms and solid tumors
- biological and molecular characterization of multiple myeloma by means of FISH gene mapping and oligonucleotide microarrays technology for global gene expression and genome-wide profiling and next generation sequencing (NGS) techniques.
- molecular characterization of chronic lymphocytic leukemia by means of FISH gene mapping and oligonucleotide microarrays technology for global gene expression and genome-wide profiling

LIST OF PUBLICATIONS 2010-2015

1. Biasiolo M., Forcato M., Possamai L., Ferrari F., Agnelli L., Lionetti M., Todoerti K., Neri A., Marchiori M., Bortoluzzi S., Bicciato S. Critical analysis of transcriptional and post-transcriptional regulatory networks in multiple myeloma. *Pac Symp Biocomput.* 2010;397-408.
2. Todoerti K., Lisignoli G., Storti P., Agnelli L., Novara F., Manferdini C., Codeluppi K., Colla S., Crugnola M., Abeltino M., Bolzoni M., Sgobba V., Facchini A., Lambertenghi-Deliliers G., Zuffardi O., Rizzoli V., Neri A., Giuliani N. Distinct transcriptional profiles characterize bone microenvironment mesenchymal cells rather than osteoblasts in relationship with multiple myeloma bone disease. *Experimental Hematology.* 2010 Feb;38(2):141-53.
3. Todoerti K., Barbui V., Pedrini O., Lionetti M., Fossati G., Mascagni P., Rambaldi A., Neri A., Introna M., Lombardi L., Golay J.: Pleiotropic anti-myeloma activity of ITF2357: inhibition of IL-6 receptor signalling and repression of mir-19a and mir-19b. *Haematologica.* 2010 Feb;95(2):260-9.
4. Piva R., Agnelli L., Pellegrino E., Todoerti K., Grosso V., Tamagno I., Fornari A., Martinoglio B., Medico E., Zamò A., Facchetti F., Ponzoni M., Geissinger E., Rosenwald A., Müller-Hermelink H.K., De Wolf-Peeters C., Piccaluga P.P., Pileri S., Neri A., Inghirami G.: Gene expression profiling uncovers molecular classifiers for the recognition of anaplastic large-cell lymphoma within peripheral T-cell neoplasms. *J Clin Oncol.* 2010 Mar 20;28(9):1583-90.
5. Morabito F., Cutrona G., Gentile M., Fabbi M., Matis S., Colombo M., Reverberi D., Megna M., Spriano M., Callea V., Vigna E., Rossi E., Lucia E., Festini G., Zupo S., Molica S., Neri A., Ferrarini M. Prognostic relevance of in vitro response to cell stimulation via surface IgD in Binet stage A CLL. *British Journal of Haematology. Br J Haematol.* 2010 Apr;149(1):160-3.
6. Molica S., Di Raimondo F., Cutrona G., Fabris S., Mauro F., Brugiatelli M., Baldini L., Musto P., Sacchi S., Cortelezzi A., Foà R., Neri A., Federico M., Ferrarini M., Morabito F.; on behalf of Gruppo Italiano Studio Linfomi (GISL): Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: the Gruppo Italiano Studio Linfomi (GISL) experience. *Leuk Res.* 2010 Aug;34(8):e217-8.
7. Cro L., Ferrario A., Lionetti M., Bertoni F., Zucal N., Nobili L., Fabris S., Todoerti K., Cortelezzi A., Guffanti A., Goldaniga M., Marcheselli L., Neri A., Lambertenghi-Deliliers G., Baldini L.: The clinical and biological features of a series of immunophenotypic variant of B-CLL. *Eur J Haematol.* 2010 Aug;85(2):120-9.
8. Giuliani N., Lisignoli G., Novara F., Storti P., Zaffaroni N., Villa R., Sammarelli G., Agnelli L., Todoerti K., Bernardo M.E., Manferdini C., Colla S., Abeltino M., Bolzoni M., Rocci A., Gabusi E., Palumbo A., Zuffardi O., Neri A., Rizzoli V. Bone osteoblastic and mesenchymal stromal cells lack primarily tumoral features in multiple myeloma patients. *Leukemia.* 2010 Jul;24(7):1368-70.
9. Chigrinova E., Kwee I., Rinaldi A., Poretti G., Pruner G., Neri A., Gaidano G., Ponzoni M., Zucca E., Bertoni F.: Non-negative matrix factorization to perform unsupervised clustering of genome wide DNA profiles in mature B cell lymphoid neoplasms. *Br J Haematol.* 2010 Jul;150(2):229-32.
10. Engelhardt M., Kleber M., Udi J., Wäsch R., Spencer A., Patriarca F., Knop S., Bruno B., Gramatzki M., Morabito F., Kropff M., Neri A., Sezer O., Hajek R., Bunjes D., Boccadoro M., Straka C., Cavo M., Polliack A., Einsele H.,

- Palumbo A.: Consensus statement from European experts on the diagnosis, management, and treatment of multiple myeloma: from standard therapy to novel approaches. *Leuk Lymphoma*. 2010 Aug;51(8):1424-43.
11. Colla S., Storti P., Donofrio G., Todoerti K., Bolzoni M., Lazzaretti M., Abeltino M., Ippolito L., Neri A., Ribatti D., Rizzoli V., Martella E., Giuliani N.: Low bone marrow oxygen tension and hypoxia-inducible factor-1alpha overexpression characterize patients with multiple myeloma: role on the transcriptional and proangiogenic profiles of CD138(+) cells. *Leukemia*. 2010 Nov;24(11):1967-70.
 12. Mosca L., Fabris S., Lionetti M., Todoerti K., Agnelli L., Morabito F., Cutrona G., Andronache A., Matis S., Ferrari F., Gentile M., Spriano M., Callea V., Festini G., Molica S., Lambertenghi Deliliers G., Bicciato S., Ferrarini M., Neri A.: Integrative genomics analyses reveal molecularly distinct subgroups of B-cell chronic lymphocytic leukemia patients with 13q14 deletion. *Clin Cancer Res*. 2010 Dec 1;16(23):5641-5653.
 13. Abeltino M., Bonomini S., Bolzoni M., Storti P., Colla S., Todoerti K., Agnelli L., Neri A., Rizzoli V., Giuliani N.: The pro-apoptotic effect of zoledronic acid is independent of either the bone microenvironment or the intrinsic resistance to bortezomib of myeloma cells and it is enhanced by the combination with arsenic trioxide. *Exp Hematol*. 2011 Jan;39(1):55-65.
 14. Walker B.A., Wardell C.P., Chiechio L., Smith E.M., Boyd K.D., Neri A., Davies F.E., Ross F.M., Morgan G.J.: Aberrant global methylation patterns affect the molecular pathogenesis and prognosis of multiple myeloma. *Blood*. 2011 Jan 13;117(2):553-62.
 15. Fabris S., Bollati V., Agnelli L., Morabito F., Motta V., Cutrona G., Matis S., Recchia A.G., Gigliotti V., Gentile M., Lambertenghi-Deliliers G., Bertazzi P.A., Ferrarini M., Neri A., Baccarelli A.: Biological and clinical relevance of quantitative global methylation of repetitive DNA sequences in chronic lymphocytic leukemia. *Epigenetics*. 2011 Feb 1;6(2):188-94.
 16. Storti P., Donofrio G., Colla S., Aioldi I., Bolzoni M., Agnelli L., Abeltino M., Todoerti K., Lazzaretti M., Mancini C., Ribatti D., Bonomini S., Franceschi V., Pistoia V., Lisignoli G., Pedrazzini A., Cavicchi O., Neri A., Rizzoli V., Giuliani N.: HOXB7 expression by myeloma cells regulates their pro-angiogenic properties in multiple myeloma patients. *Leukemia*. 2011 Mar;25(3):527-37.
 17. Fracchiolla N.S., Todoerti K., Bertazzi P.A., Servida F., Corradini P., Carniti C., Colombi A., Pesatori A., Neri A., Lambertenghi-Deliliers G.: Dioxin exposure of human CD34(+) hemopoietic cells induces gene expression modulation that recapitulates its in vivo clinical and biological effects. *Toxicology*. 2011 Apr 28;283(1):18-23.
 18. Civallero M., Cosenza M., Neri A., Bari A.: Genomic profiling of enzastaurin-treated B cell lymphoma RL cells. *Hematol Oncol*. 2011 Sep;29(3):154-6.
 19. Poretti G., Kwee I., Bernasconi B., Rancoita P.M., Rinaldi A., Capella C., Zucca E., Neri A., Tibiletti M.G., Bertoni F.: Chromosome 11q23.1 is an unstable region in B-cell tumor cell lines. *Leuk Res*. 2011 Jun;35(6):808-13.
 20. Colombo M., Cutrona G., Reverberi D., Fabris S., Neri A., Fabbi M., Quintana G., Quarta G., Ghiootto F., Fais F., Ferrarini M.: Intraclonal cell expansion and selection driven by B cell receptor in chronic lymphocytic leukemia. *Mol Med*. 2011;17(7-8):834-9.
 21. Fabris S., Scariolla O., Morabito F., Cifarelli R.A., Dininno C., Cutrona G., Matis S., Recchia A.G., Gentile M., Ciceri G., Ferrarini M., Ciancio A., Mannarella C., Neri A., Fragasso A.: Multiplex ligation-dependent probe amplification and fluorescence in situ hybridization to detect chromosomal abnormalities in chronic lymphocytic leukemia: a comparative study. *Genes Chromosomes Cancer*. 2011 Sep;50(9):726-34.
 22. Barreca A., Lasorsa E., Riera L., Machiorlatti R., Piva R., Ponzoni M., Kwee I., Bertoni F., Piccaluga P.P., Pileri S.A., Inghirami G.; European T-Cell Lymphoma Study Group.

Collaborators

Barreca A, Chiarle R, Cuccuru G, Inghirami G, Martinoglio B, Medico E, Pellegrino E, Piva R, Ruberto ML, Voenen C, Fornari A, Novero D, Chilosì M, Zamò A, Facchetti F, Lonardi S, De Chiara A, Fulciniti F, Doglioni C, Ponzoni M, Agnelli L, Neri A, Todoerti K, Piccaluga PP, Pileri S, Falini B, Tiacci E, Van Loo P, Tousseyn T, De Wolf-Peeters C, Geissinger E, Muller-Hermelink HK, Rosenwald A, Piris MA, Maria E R.: Anaplastic lymphoma kinase in human cancer. *J Mol Endocrinol*. 2011 Jul 4;47(1):R11-23. Print 2011. Review.

23. Inghirami G., Pileri S.A.; European T-Cell Lymphoma Study Group.

Collaborators

- Chiarle R., Cuccuru G., Inghirami G., Martinoglio B., Medico E., Pellegrino E., Piva R., Ruberto M.L., Fornari A., Novero D., Chilosì M., Zamò A., Facchetti F., Lonardi S., De Chiara A., Fulciniti F., Doglioni C., Ponzoni M., Agnelli L., Neri A., Todoerti K., Agostinelli C., Piccaluga P.P., Pileri S., Falini B., Tiacci E., Van Loo P., Tousseyn T., De Wolf-Peeters C., Geissinger E., Muller-Hermelink H.K., Rosenwald A., Piris M.A., Rodriguez M.E.: Anaplastic large-cell lymphoma. *Semin Diagn Pathol.* 2011 Aug;28(3):190-201.
24. Maura F., Cutrona G., Fabris S., Colombo M., Tuana G., Agnelli L., Matis S., Lionetti M., Gentile M., Recchia A.G., Di Raimondo F., Musolino C., Ilariucci F., Di Renzo N., Pesce E., Molica S., Federico M., Corteletti A., Morabito F., Ferrarini M., Neri A.: Relevance of stereotyped B-cell receptors in the context of the molecular, cytogenetic and clinical features of chronic lymphocytic leukemia. *PLoS One.* 2011;6(8):e24313. Epub 2011 Aug 29.
25. Biasiolo M., Sales G., Lionetti M., Agnelli L., Todoerti K., Bisognin A., Coppe A., Romualdi C., Neri A., Bortoluzzi S.: Impact of host genes and strand selection on miRNA and miRNA* expression. *PLoS One.* 2011;6(8):e23854. Epub 2011 Aug 31.
26. Agnelli L., Forcato M., Ferrari F., Tuana G., Todoerti K., Walker B.A., Morgan G.J., Lombardi L., Bicciato S., Neri A.: The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma. *Clin Cancer Res.* 2011 Dec 1;17(23):7402-12.
27. Agnelli L., Storti P., Todoerti K., Sammarelli G., Dalla Palma B., Bolzoni M., Rocci A., Piazza F., Semenzato G., Palumbo A., Neri A., Giuliani N.: Overexpression of HOXB7 and homeobox genes characterizes multiple myeloma patients lacking the major primary immunoglobulin heavy chain locus translocations. *Am J Hematol.* 2011 Dec;86(12):E64-6. doi: 10.1002/ajh.22164.
28. Morabito F., De Filippi R., Laurenti L., Zirlik K., Recchia A.G., Gentile M., Morelli E., Vigna E., Gigliotti V., Calemma R., Amoroso B., Neri A., Cutrona G., Ferrarini M., Molica S., Del Poeta G., Tripodo C., Pinto A.: The cumulative amount of serum free light chain is a strong prognosticator in chronic lymphocytic leukemia. *Blood.* 2011 Dec 8;118(24):6353-61.
29. Molica S., Gentile M., Mauro F.R., Brugiatelli M., Federico M., Sperduti I., Neri A., Ferrarini M., Foà R., Morabito F. An increased number of individuals with clinically recognized monoclonal B-cell lymphocytosis characterizes a recent database of Chronic Lymphocytic Leukemia Rai stage 0. *Acta Haematol.* 2012 Jan 19;127(3):149-151.
30. Gritti G., Reda G., Maura F., Piciocchi A., Baldini L., Molica S., Neri A., Corteletti A.: Low dose alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia patients. *Leukemia & Lymphoma.* 2012 March;53(3):424-429.
31. Visco C., Maura F., Tuana G., Agnelli L., Lionetti M., Fabris S., Novella E., Giaretta I., Reda G., Barcellini W., Baldini L., Neri A., Rodeghiero F., Corteletti A.: Immune thrombocytopenia in patients with chronic lymphocytic leukemia is associated with stereotyped B-cell receptors. *Clin Cancer Res.* 2012 Apr 1;18(7):1870-8.
32. Musto P., Pagano L., Petrucci M.T., Morabito F., Caravita T., Di Raimondo F., Baldini L., Tosi P., Bringhen S., Offidani M., Omede' P., Neri A., D'Auria F., Bochicchio G.B., Cavo M., Boccadoro M., Palumbo A.: Primary plasma cell leukemia in the era of new drugs: has something changed? *Crit Rev Oncol Hematol.* 2012 May;82(2):141-9.
33. Giuliani N., Ferretti M., Bolzoni M., Storti P., Lazzaretti M., Dalla Palma B., Bonomini S., Martella E., Agnelli L., Neri A., Ceccarelli F., Palumbo C.: Increased osteocyte death in multiple myeloma patients: role in myeloma-induced osteoclast formation. *Leukemia.* 2012 Jun;26(6):1391-401.
34. Amaru Calzada A., Todoerti K., Donadoni L., Pellicoli A., Tuana G., Gatta R., Neri A., Finazzi G., Mantovani R., Rambaldi A., Introna M., Lombardi L., Golay J.; on behalf of the AGIMM Investigators: The HDAC inhibitor

- Givinostat modulates the hematopoietic transcription factors NFE2 and C-MYB in JAK2(V617F) myeloproliferative neoplasm cells. *Exp Hematol.* 2012 Aug;40(8):634-645.
35. Agnelli L., Mereu E., Pellegrino E., Limongi T., Kwee I., Bergaggio E., Ponzoni M., Zamò A., Iqbal J., Piccaluga P.P., Neri A., Chan J.C., Pileri S., Bertoni F., Inghirami G., Piva R.: Identification of a three-gene model as a powerful diagnostic tool for the recognition of ALK negative ALCL. *Blood.* 2012 Aug 9;120(6):1274-1281.
36. Lionetti M., Agnelli L., Lombardi L., Neri A.: MicroRNAs in the Pathobiology of Multiple Myeloma. *Curr Cancer Drug Targets.* 2012 Sep 1;12(7):823-37.
37. Tagliaferri P., Rossi M., Di Martino M.T., Amodio N., Leone E., Gulla A., Neri A., Tassone P.: Promises and Challenges of MicroRNA-based Treatment of Multiple Myeloma. *Curr Cancer Drug Targets.* 2012 Sep 1;12(7):838-46.
38. Scarfò L., Zibellini S., Tedeschi A., Maura F., Neri A., Bertazzoni P., Sarina B., Nalli G., Motta M., Rossini F., Corteletti A., Montillo M., Orlandi E., Ghia P.: Impact of B-cell count and imaging screening in cMBL: any need to revise the current guidelines? *Leukemia.* 2012 Jul;26(7):1703-7.
39. Di Martino M.T., Leone E., Amodio N., Foresta U., Lionetti M., Pitari M.R., Gallo Cantafio M.E., Gullà A., Conforti F., Morelli E., Tomaino V., Rossi M., Negrini M., Ferrarini M., Caraglia M., Shammas M.A., Munshi N.C., Anderson K.C., Neri A., Tagliaferri P., Tassone P.: Synthetic miR-34a mimics as a novel therapeutic agent for Multiple Myeloma: in vitro and in vivo evidence. *Clin Cancer Res.* 2012 Nov 15;18(22):6260-6270.
40. Amodio N., Leotta M., Bellizzi D., Di Martino M.T., D'Aquila P., Lionetti M., Fabiani F., Leone E., Gullà A.M., Passarino G., Caraglia M., Negrini M., Neri A., Giordano A., Tagliaferri P., Tassone P.: DNA-demethylating and anti-tumor activity of synthetic miR-29b mimics in multiple myeloma. *Oncotarget.* 2012 Oct;3(10):1246-58.
41. Amodio N., Di Martino M.T., Foresta U., Leone E., Lionetti M., Leotta M., Gullà A.M., Pitari M.R., Conforti F., Rossi M., Agosti V., Fulciniti M., Misso G., Morabito F., Ferrarini M., Neri A., Caraglia M., Munshi N.C., Anderson K.C., Tagliaferri P., Tassone P.: miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1. *Cell Death Dis.* 2012 Nov 29;3:e436. doi: 10.1038/cddis.2012.175.
42. Ronchetti D., Todoerti K., Tuana G., Agnelli L., Mosca L., Lionetti M., Fabris S., Colapietro P., Miozzo M., Ferrarini M., Tassone P., Neri A.: The expression pattern of small nucleolar and small Cajal body-specific RNAs characterizes distinct molecular subtypes of multiple myeloma. *Blood Cancer J.* 2012 Nov 23;2:e96. doi: 10.1038/bcj.2012.41.
43. Blotta S., Jakubikova J., Calimeri T., Roccaro A.M., Amodio N., Azab A.K., Foresta U., Mitsiades C.S., Rossi M., Todoerti K., Molica S., Morabito F., Neri A., Tagliaferri P., Tassone P., Anderson K.C., Munshi N.C.: Canonical and non canonical Hedgehog pathway in the pathogenesis of multiple myeloma. *Blood.* 2012 Dec 13;120(25):5002-13.
44. Fabris S., Mosca L., Cutrona G., Lionetti M., Agnelli L., Ciceri G., Barbieri M., Maura F., Matis S., Colombo M., Gentile M., Recchia A.G., Anna Pesce E., Di Raimondo F., Musolino C., Gobbi M., Di Renzo N., Mauro F.R., Brugiatelli M., Ilariucci F., Lipari M.G., Angrilli F., Consoli U., Fragasso A., Molica S., Festini G., Vincelli I., Corteletti A., Federico M., Morabito F., Ferrarini M., Neri A.: Chromosome 2p gain in monoclonal B-cell lymphocytosis and in early stage chronic lymphocytic leukemia. *Am J Hematol.* Am J Hematol. 2013 Jan;88(1):24-31.
45. Mosca L., Musto P., Todoerti K., Barbieri M., Agnelli L., Fabris S., Tuana G., Lionetti M., Bonaparte E., Sirchia S.M., Grieco V., Bianchino G., D'Auria F., Statuto T., Mazzoccoli C., De Luca L., Petrucci M.T., Morabito F., Offidani M., Di Raimondo F., Falcone A., Caravita T., Omedè P., Boccadoro M., Palumbo A., Neri A.: Genome-wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles. *Am J Hematol.* 2013 Jan;88(1):16-23.
46. Ripamonti F., Albano L., Rossini A., Borrelli S., Fabris S., Mantovani R., Neri A., Balsari A., Magnifico A., Tagliabue E.: EGFR through STAT3 is a player in Δnp63α expression and together sustain tumor-initiating cell proliferation in squamous cell carcinomas. *J Cell Physiol.* 2013 Apr;228(4):871-8.

47. Maura F., Visco C., Falisi E., Reda G., Fabris S., Agnelli L., Tuana G., Lionetti M., Guercini N., Novella E., Nichele I., Montaldi A., Autore F., Gregorini A., Barcellini W., Callea V., Mauro F.R., Laurenti L., Foà R., Neri A., Rodeghiero F., Corteletti A.: B-cell receptor configuration and adverse cytogenetics are associated with autoimmune hemolytic anemia in chronic lymphocytic leukemia. *Am J Hematol.* 2013 Jan;88(1):32-6.
48. Bolzoni M., Donofrio G., Storti P., Guasco D., Toscani D., Lazzaretti M., Bonomini S., Agnelli L., Capocefalo A., Palma B.D., Neri A., Nicolini F., Lisignoli G., Russo F., Colla S., Aversa F., Giuliani N.: Myeloma cells inhibit non-canonical Wnt co-receptor Ror2 expression in human bone marrow osteoprogenitor cells: effect of Wnt5a/Ror2 pathway activation on the osteogenic differentiation impairment induced by myeloma cells. *Leukemia.* 2013 Feb;27(2):451-63.
49. Molica S., Giannarelli D., Gentile M., Cutrona G., Di Renzo N., Di Raimondo F., Neri A., Federico M., Ferrarini M., Morabito F.: External validation on a prospective basis of a nomogram for predicting the time to first treatment in patients with chronic lymphocytic leukemia. *Cancer.* 2013 Mar 15;119(6):1177-85.
50. Di Martino M.T., Gullà A., Cantafio M.E., Lionetti M., Leone E., Amodio N., Guzzi P.H., Foresta U., Conforti F., Cannataro M., Neri A., Giordano A., Tagliaferri P., Tassone P.: In Vitro and in Vivo Anti-tumor Activity of miR-221/222 Inhibitors in Multiple Myeloma. *Oncotarget.* 2013 Feb;4(2):242-55.
51. Visco C., Moretta F., Falisi E., Facco M., Maura F., Novella E., Nichele I., Finotto S., Giaretta I., Ave E., Perbellini O., Guercini N., Scupoli M.T., Trentin L., Trimarco V., Neri A., Semenzato G., Rodeghiero F., Pizzolo G., Ambrosetti A.: Double productive immunoglobulin sequence rearrangements in patients with chronic lymphocytic leukemia. *Am J Hematol.* 2013 Apr;88(4):277-82.
52. Bolzoni M., Storti P., Bonomini S., Todoerti K., Guasco D., Toscani D., Agnelli L., Neri A., Rizzoli V., Giuliani N.: Immunomodulatory drugs lenalidomide and pomalidomide inhibit multiple Myeloma-induced osteoclast formation and the RANKL/OPG ratio in the myeloma microenvironment targeting the expression of adhesion molecules. *Exp Hematol.* 2013 Apr;41(4):387-397.
53. Leone E., Morelli E., Di Martino M.T., Amodio N., Foresta U., Gulla' A., Rossi M., Neri A., Giordano A., Munshi N.C., Anderson K.C., Tagliaferri P., Tassone P.: Targeting miR-21 inhibits in vitro and in vivo multiple myeloma cell growth. *Clin Cancer Res.* 2013 Apr 15;19(8):2096-2106.
54. Ezponda T., Popovic R., Shah M.Y., Martinez-Garcia E., Zheng Y., Min D.J., Will C., Neri A., Kelleher N.L., Yu J., Licht J.D.: The histone methyltransferase MMSET/WHSC1 activates TWIST1 to promote an epithelial-mesenchymal transition and invasive properties of prostate cancer. *Oncogene.* 2013 Jun 6;32(23):2882-90.
55. Scavullo C., Servida F., Lecis D., Onida F., Drago C., Ferrante L., Seneci P., Barcellini W., Lionetti M., Todoerti K., Neri A., Delia D., Deliliers G.L.: Single-agent Smac-mimetic compounds induce apoptosis in B chronic lymphocytic leukaemia (B-CLL). *Leuk Res.* 2013 Jul;37(7):809-15.
56. Molica S., Giannarelli D., Gentile M., Cutrona G., Di Renzo N., Di Raimondo F., Neri A., Federico M., Ferrarini M., Morabito F.: The utility of two prognostic models for predicting time to first treatment in early chronic lymphocytic leukemia patients: Results of a comparative analysis. *Leuk Res.* 2013 Aug;37(8):943-7.
57. Todoerti K., Agnelli L., Fabris S., Lionetti M., Tuana G., Mosca L., Lombardi L., Grieco V., Bianchino G., D'Auria F., Statuto T., Mazzoccoli C., De Luca L., Petrucci M.T., Morabito F., Offidani M., Di Raimondo F., Falcone A., Omedè P., Tassone P., Boccadoro M., Palumbo A., Neri A., Musto P.: Transcriptional characterization of a prospective series of primary plasma cell leukemia revealed signatures associated with tumor progression and poorer outcome. *Clin Cancer Res.* 2013 Jun 15;19(12):3247-3258.
58. Lionetti M., Musto P., Di Martino M.T., Fabris S., Agnelli L., Todoerti K., Tuana G., Mosca L., Gallo Cantafio M.E., Grieco V., Bianchino G., D'Auria F., Statuto T., Mazzoccoli C., De Luca L., Petrucci M.T., Offidani M., Di Raimondo F., Falcone A., Caravita T., Omedè P., Morabito F., Tassone P., Boccadoro M., Palumbo A., Neri A.: Biological and clinical relevance of miRNA expression signatures in primary plasma cell leukemia. *Clin Cancer Res.* 2013 Jun 15;19(12):3130-3142.
59. Agnelli L., Tassone P., Neri A.: Molecular profiling of multiple myeloma: from gene expression analysis to next-generation sequencing. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S55-68.
60. Amodio N., Di Martino M.T., Neri A., Tagliaferri P., Tassone P.: Non-coding RNA: a novel opportunity for the personalized treatment of multiple myeloma. *Expert Opin Biol Ther.* 2013 Jun;13 Suppl 1:S125-37.
61. Gentile M., Cutrona G., Fabris S., Pesce E.A., Baldini L., Di Raimondo F., Musolino C., Di Tonno P., Di Renzo N., Molica S., Brugiatelli M., Ilariucci F., Zupo S., Matis S., Maura F., Vigna E., Angrilli F., Recchia A.G., Quarta G.,

- Iannitto E., Fragasso A., Musto P., Spriano M., Vincelli I., Vallisa D., Cortelezz A., Mauro F.R., Foà R., Federico M., Neri A., Ferrarini M., Morabito F.: Total body computed tomography scan in the initial work-up of binet stage a chronic lymphocytic leukemia patients: Results of the prospective, multicenter o-ctl1-gisl study. *Am J Hematol.* 2013 Jul;88(7):539-44. doi: 10.1002/ajh.23448. PMID: 23553682.
62. Wu P., Agnelli L., Walker B.A., Todoerti K., Lionetti M., Johnson D.C., Kaiser M., Mirabella F., Wardell C., Gregory W.M., Davies F.E., Brewer D., Neri A., Morgan G.J.: Improved risk stratification in myeloma using a microRNA-based classifier. *Br J Haematol.* 2013 Aug;162(3):348-59.
63. Storti P., Bolzoni M., Donofrio G., Airolidi I., Guasco D., Toscani D., Martella E., Lazzaretti M., Mancini C., Agnelli L., Patrene K., Maiga S., Franceschi V., Colla S., Anderson J., Neri A., Amiot M., Aversa F., Roodman G.D., Giuliani N.: Hypoxia-inducible factor (hif)-1 α suppression in myeloma cells blocks tumoral growth in vivo inhibiting angiogenesis and bone destruction. *Leukemia.* 2013 Aug;27(8):1697-706.
64. Ronchetti D., Mosca L., Cutrona G., Tuana G., Gentile M., Fabris S., Agnelli L., Ciceri G., Matis S., Massucco C., Colombo M., Reverberi D., Recchia A.G., Bossio S., Negrini M., Tassone P., Morabito F., Ferrarini M., Neri A.: Small nucleolar RNAs as new biomarkers in chronic lymphocytic leukemia. *BMC Med Genomics.* 2013 Sep 3;6(1):27.
65. Morabito F., Mosca L., Cutrona G., Agnelli L., Tuana G., Ferracin M., Zagatti B., Lionetti M., Fabris S., Maura F., Matis S., Gentile M., Vigna E., Colombo M., Massucco C., Recchia A.G., Bossio S., De Stefano L., Ilariucci F., Musolino C., Molica S., Di Raimondo F., Cortelezz A., Tassone P., Negrini M., Monti S., Rossi D., Gaidano G., Ferrarini M., Neri A.: Clinical monoclonal B lymphocytosis versus Rai 0 chronic lymphocytic leukemia: a comparison of cellular, cytogenetic, molecular, and clinical features. *Clin Cancer Res.* 2013 Nov 1;19(21):5890-900.
66. Amodio N., Bellizzi D., Leotta M., Raimondi L., Biamonte L., D'Aquila P., Di Martino M.T., Calimeri T., Rossi M., Lionetti M., Leone E., Passarino G., Neri A., Giordano A., Tagliaferri P., Tassone P.: miR-29b induces SOCS-1 expression by promoter demethylation and negatively regulates migration of multiple myeloma and endothelial cells. *Cell Cycle.* 2013 Dec 1;12(23):3650-62.
67. Musto P., Simeon V., Martorelli M.C., Petrucci M.T., Cascavilla N., Di Raimondo F., Caravita T., Morabito F., Offidani M., Olivieri A., Benevoli G., Mina R., Guariglia R., D'Arena G., Mansuetto G., Filardi N., Nobile F., Levi A., Falcone A., Cavalli M., Pietrantuono G., Villani O., Bringhen S., Omedè P., Lerose R., Agnelli L., Todoerti K., Neri A., Boccadoro M., Palumbo A.: Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia. *Leukemia.* 2014 Jan;28(1):222-5. doi: 10.1038/leu.2013.241. PMID: 23958922.
68. Verdelli D., Nobili L., Todoerti K., Mosca L., Fabris S., D'Anca M., Pellegrino E., Piva R., Inghirami G., Capelli C., Intronza M., Baldini L., Chiaramonte R., Lombardi L., Neri A.: Molecular events underlying interleukin-6 independence in a subclone of the CMA-03 multiple myeloma cell line. *Genes Chromosomes Cancer.* 2014 Feb;53(2):154-67. doi: 10.1002/gcc.22127. PMID: 24327544.
69. Ronchetti D., Tuana G., Rinaldi A., Agnelli L., Cutrona G., Mosca L., Fabris S., Matis S., Colombo M., Gentile M., Grazia Recchia A., Kwee I., Bertoni F., Morabito F., Ferrarini M., Neri A.: Distinct patterns of global promoter methylation in early stage chronic lymphocytic leukemia. *Genes Chromosomes Cancer.* 2014 Mar;53(3):264-73. doi: 10.1002/gcc.22139. PMID: 24347044.
70. Cortelezz A., Sciumè M., Liberati A.M., Vincenti D., Cuneo A., Reda G., Laurenti L., Zaja F., Marasca R., Chiarenza A., Gritti G., Orsucci L., Storti S., Angelucci E., Cascavilla N., Gobbi M., Mauro F.R., Morabito F., Fabris S., Piciocchi A., Vignetti M., Neri A., Rossi D., Giannarelli D., Guarini A., Foà R.: Bendamustine in combination with ofatumumab in relapsed or refractory chronic lymphocytic leukemia: a GIMEMA multicenter phase II trial. *Leukemia.* 2014 Mar;28(3):642-8. doi: 10.1038/leu.2013.334. PMID: 24220274.
71. Falisi E., Novella E., Visco C., Guercini N., Maura F., Giaretta I., Pomponi F., Nichele I., Finotto S., Montaldi A., Neri A., Rodeghiero F.: B-cell receptor configuration and mutational analysis of patients with chronic lymphocytic leukaemia and trisomy 12 reveal recurrent molecular abnormalities. *Hematol Oncol.* 2014 Mar;32(1):22-30. doi: 10.1002/hon.2086. PMID: 23861036.
72. Visco C., Cortelezz A., Moretta F., Falisi E., Maura F., Finotto S., Barcellini W., Ambrosetti A., Neri A., Ruggeri M., Rodeghiero F.: Autoimmune cytopenias in chronic lymphocytic leukemia at disease presentation in the modern treatment era: is stage C always stage C? *Leuk Lymphoma.* 2014 Jun;55(6):1261-5. doi: 10.3109/10428194.2013.834054.
73. Lionetti M., Fabris S., Cutrona G., Agnelli L., Ciardullo C., Matis S., Ciceri G., Colombo M., Maura F., Mosca L., Gentile M., Recchia A.G., Ilariucci F., Musolino C., Molica S., Di Raimondo F., Cortelezz A., Rossi D., Gaidano

- G., Morabito F., Ferrarini M., Neri A.: High-throughput sequencing for the identification of NOTCH1 mutations in early stage chronic lymphocytic leukaemia: biological and clinical implications. *Br J Haematol.* 2014 Jun;165(5):629-39. doi: 10.1111/bjh.12800.
74. Hoxha M., Fabris S., Agnelli L., Bollati V., Cutrona G., Matis S., Recchia A.G., Gentile M., Corteletti A., Morabito F., Bertazzi P.A., Ferrarini M., Neri A.: Relevance of telomere/telomerase system impairment in early stage chronic lymphocytic leukemia. *Genes Chromosomes Cancer.* 2014 Jul;53(7):612-21.
75. Gentile M., Cutrona G., Mosca L., Matis S., Fabris S., Lionetti M., Ilariucci F., Zupo S., Musolino C., Levato L., Molica S., Di Raimondo F., Vincelli I., Di Renzo N., Pesce E.A., Angrilli F., Federico M., Neri A., Ferrarini M., Morabito F.: Prospective validation of a risk score based on biological markers for predicting progression free survival in binet stage a chronic lymphocytic leukemia patients: Results of the multicenter O-CLL1-GISL study. *Am J Hematol.* 2014 Jul;89(7):743-50. doi: 10.1002/ajh.23729. PMID: 24711230.
76. Cottini F., Hidemitsu T., Xu C., Sattler M., Dori M., Agnelli L., Ten Hacken E., Bertilaccio M.T., Antonini E., Neri A., Ponzoni M., Marcatti M., Richardson P.G., Carrasco R., Kimmelman A.C., Wong K.K., Caligaris-Cappio F., Blandino G., Kuehl W.M., Anderson K.C., Tonon G.: Rescue of Hippo coactivator YAP1 triggers DNA damage-induced apoptosis in hematological cancers. *Nat Med.* 2014 Jun;20(6):599-606. doi: 10.1038/nm.3562. PMID: 24813251.
77. Leotta M., Biamonte L., Raimondi L., Ronchetti D., Martino M.T., Botta C., Leone E., Pitari M.R., Neri A., Giordano A., Tagliaferri P., Tassone P., Amodio N.: A p53-dependent tumor suppressor network is induced by selective miR-125a-5p inhibition in multiple myeloma cells in vitro. *J Cell Physiol.* 2014 Dec;229(12):2106-16. doi: 10.1002/jcp.24669. PMID: 24819167.
78. Raimondi L., Amodio N., Di Martino M.T., Altomare E., Leotta M., Caracciolo D., Gullà A., Neri A., Taverna S., D'Aquila P., Alessandro R., Giordano A., Tagliaferri P., Tassone P.: Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity. *Oncotarget.* 2014 May 30;5(10):3039-54.
79. Negrini M., Cutrona G., Bassi C., Fabris S., Zagatti B., Colombo M., Ferracin M., D'Abundo L., Saccenti E., Matis S., Lionetti M., Agnelli L., Gentile M., Recchia A.G., Bossio S., Reverberi D., Rigolin G.M., Calin G.A., Sabbioni S., Russo G., Tassone P., Morabito F., Ferrarini M., Neri A.: microRNAome expression in chronic lymphocytic leukemia: comparison with normal B cell subsets and correlations with prognostic and clinical parameters. *Clin Cancer Res.* 2014 Aug 1;20(15):4141-53. doi: 10.1158/1078-0432.CCR-13-2497. PMID: 24916701.
80. Visco C., Barcellini W., Maura F., Neri A., Corteletti A., Rodeghiero F.: Autoimmune cytopenias in chronic lymphocytic leukemia. *Am J Hematol.* 2014 Nov;89(11):1055-62. doi: 10.1002/ajh.23785.
81. Colombo M., Thümmler K., Mirandola L., Garavelli S., Todoerti K., Apicella L., Lazzari E., Lancellotti M., Platonova N., Akbar M., Chiriva-Internati M., Soutar R., Neri A., Goodyear C.S., Chiaramonte R.: Notch signaling drives multiple myeloma induced osteoclastogenesis. *Oncotarget.* 2014 Nov 15;5(21):10393-406. PMID: 25257302.
82. Morabito F., Cutrona G., Gentile M., Fabris S., Matis S., Vigna E., Todoerti K., Colombo M., Recchia A.G., Bossio S., De Stefano L., Ilariucci F., Corteletti A., Consoli U., Vincelli I., Pesce E.A., Musolino C., Molica S., Di Raimondo F., Neri A., Ferrarini M.: Is ZAP70 still a key prognostic factor in early stage chronic lymphocytic leukaemia? Results of the analysis from a prospective multicentre observational study. *Br J Haematol.* 2015 Feb;168(3):455-9. doi: 10.1111/bjh.13117. PMID: 25208809.
83. Piva R., Deaglio S., Famà R., Buonincontri R., Scarfò I., Bruscaggin A., Mereu E., Serra S., Spina V., Brusa D., Garaffo G., Monti S., Dal Bo M., Marasca R., Arcaini L., Neri A., Gattei V., Paulli M., Tiacchi E., Bertoni F., Pileri S.A., Foà R., Inghirami G., Gaidano G., Rossi D.: The krüppel-like factor 2 transcription factor gene is recurrently mutated in splenic marginal zone lymphoma. *Leukemia.* 2015 Feb;29(2):503-7. doi: 10.1038/leu.2014. PMID: 25283840.
84. Gentile M., Cutrona G., Molica S., Ilariucci F., Mauro F.R., Di Renzo N., Di Raimondo F., Vincelli I., Todoerti K., Matis S., Musolino C., Fabris S., Lionetti M., Levato L., Zupo S., Angrilli F., Consoli U., Festini G., Longo G., Corteletti A., Musto P., Federico M., Neri A., Ferrarini M., Morabito F.: Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukaemia patients: results of the multicenter O-CLL1-GISL study. *Eur J Haematol.* 2015 Mar 9. doi: 10.1111/ejh.12545. PMID: 25753656 [Epub ahead of print]

85. Maura F., Mosca L., Fabris S., Cutrona G., Matis S., Lionetti M., Agnelli L., Barbieri M., D'Anca M., Manzoni M., Colombo M., Massucco C., Reverberi D., Gentile M., Recchia A.G., Bossio S., Ilariucci F., Musolino C., Di Raimondo F., Corteletti A., Morabito F., Ferrarini M., Neri A.: Insulin Growth Factor 1 Receptor Expression Is Associated with NOTCH1 Mutation, Trisomy 12 and Aggressive Clinical Course in Chronic Lymphocytic Leukaemia. *PLoS One*. 2015 Mar 18;10(3):e0118801. doi: 10.1371/journal.pone.0118801. eCollection 2015. PMID: 25786252.
86. Maura F., Cutrona G., Mosca L., Matis S., Lionetti M., Fabris S., Agnelli L., Colombo M., Massucco C., Ferracin M., Zagatti B., Reverberi D., Gentile M., Recchia A.G., Bossio S., Rossi D., Gaidano G., Molica S., Corteletti A., Di Raimondo F., Negrini M., Tassone P., Morabito F., Ferrarini M., Neri A.: ASSOCIATION BETWEEN GENE AND MIRNA EXPRESSION PROFILES AND STEREOTYPED SUBSET #4 B-CELL RECEPTOR IN CHRONIC LYMPHOCYTIC LEUKEMIA. *Leuk Lymphoma*. 2015 Apr 10:1-51. PMID: 25860243 [Epub ahead of print]
87. Segalla S., Pivetti S., Todoerti K., Chudzik M.A., Giuliani E.C., Lazzaro F., Volta V., Lazarevic D., Musco G., Muzi-Falconi M., Neri A., Biffo S., Tonon G.: The ribonuclease DIS3 promotes let-7 miRNA maturation by degrading the pluripotency factor LIN28B mRNA. *Nucleic Acids Res*. 2015 May 26;43(10):5182-93. doi: 10.1093/nar/gkv387. PMID: 25925570.
88. Morelli E., Leone E., Cantafio M.E., Di Martino M.T., Amodio N., Biamonte L., Gullà A., Foresta U., Pitari M.R., Botta C., Rossi M., Neri A., Munshi N.C., Anderson K.C., Tagliaferri P., Tassone P.: Selective targeting of IRF4 by synthetic microRNA-125b-5p mimics induces anti-multiple myeloma activity in vitro and in vivo. *Leukemia*. 2015 May 19. doi: 10.1038/leu.2015.124. PMID: 25987254. [Epub ahead of print]
89. Morabito F., Cutrona G., Mosca L., D'Anca M., Matis S., Gentile M., Vigna E., Colombo M., Recchia A.G., Bossio S., De Stefano L., Maura F., Manzoni M., Ilariucci F., Consoli U., Vincelli I., Musolino C., Corteletti A., Molica S., Ferrarini M., Neri A.: Surrogate molecular markers for IGHV mutational status in chronic lymphocytic leukemia for predicting time to first treatment. *Leuk Res*. 2015 May 19. pii: S0145-2126(15)00149-6. doi: 10.1016/j.leukres.2015.05.005. PMID: 26038121. [Epub ahead of print]
90. Cifola I., Lionetti M., Pinatel E., Todoerti K., Mangano E., Pietrelli A., Fabris S., Mosca L., Simeon V., Petrucci M.T., Morabito F., Offidani M., Di Raimondo F., Falcone A., Caravita T., Battaglia C., De Bellis G., Palumbo A., Musto P., Neri A.: Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns. *Oncotarget*. 2015 May 25. PMID: 26046463. [Epub ahead of print]
91. Platonova N., Manzo T., Mirandola L., Colombo M., Calzavara E., Vigolo E., Cermisoni GC, De Simone D., Garavelli S., Cecchinato V., Lazzari E., Neri A., Chiaramonte R.: PI3K/AKT signaling inhibits NOTCH1 lysosome-mediated degradation. *Genes Chromosomes Cancer*. 2015 Jun 6. doi: 10.1002/gcc.22264. PMID: 26052821. [Epub ahead of print]
92. Di Martino M.T., Guzzi P.H., Caracciolo D., Agnelli L., Neri A., Walker B.A., Morgan G.J., Cannataro M., Tassone P., Tagliaferri P.: Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma. *Oncotarget*. 2015 May 27. PMID: 26056083. [Epub ahead of print]